Navigation Links
MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
Date:9/11/2007

efficacy of CLS001 in up to 240 subjects with papulopustular rosacea. The primary efficacy endpoint is the mean percent reduction in the number of inflammatory lesions. This study is expected to be completed by the end of 2007.

MX-2401 (IV lipopeptide; treatment of gram-positive bacterial infections): Good Laboratory Practices ("GLP") non-clinical studies were initiated in April 2007. Timing for completion of the GLP studies is dependent upon (1) additional manufacturing process development work; (2) initiation of the remaining required GLP studies; and (3) financial resources. Prior to initiating clinical trials in humans with MX-2401 the Company will need to complete the GLP studies, manufacture clinical trial GMP quality MX-2401, submit and obtain regulatory approval for initiating clinical studies, and various other activities. A $9.3 million investment commitment from Technology Partnerships Canada is associated with this program.

MX-4565 (small molecule; treatment of neurodegenerative diseases): In June 2007 we were awarded a grant from the Michael J. Fox Foundation to fund research in our MX-4565 program. The grant award agreement provides Elan Pharmaceuticals with a limited right to license the technology arising from the project for certain uses in the field of human disease.

Annual General Meeting: The Company hosted its 2007 Annual General Meeting yesterday. Re-elected to the board of directors were: David Scott (Chairman), Michael Abrams, Jim DeMesa, Richard DeVries, Alistair Duncan, Steve Gillis, Colin Mallet, Walter Moos, and Keith Schilit.

Other Matters: Further to the notice of early termination of our Vancouver facility lease due to a redevelopment of the site the Company has entered into an offer to lease approximately 5,000 square feet of space (currently office space, no labs) in close proximity to the existing facility and has made an offer to lease approximately 6,000 to 9,000 square feet of lab space in the Vancouver a
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... a meter in size, are around us every day. ... as in some innovative early cancer treatments, but they ... traffic emissions, cosmetics, sunscreen and electronics. , A team ... by Lan Yang, PhD, the Das Family Career Development ... collaborators at Tsinghua University in China have developed a ...
(Date:9/2/2014)... September 02, 2014 Press attending the ... to take advantage of the people and events in ... below are available throughout the day. Additionally, we will ... POET and DSM representatives as well as representatives from ... is appreciated. , Please remember to RSVP to ...
(Date:9/2/2014)... -- Technology Applications International Corporation (the "Company" or "NUUU")(OTC BB: ... Inc. has signed an additional exclusive licensing agreement with ... Johnson Space Center in Houston , ... Charles J. Scimeca , NUUU,s ... latest, exclusive agreement with NASA. In addition to our ...
(Date:9/2/2014)... Sept. 2, 2014 Orexigen Therapeutics, Inc. (Nasdaq: ... Patent and Trademark Office (PTO) has issued a patent ... for weight loss. NB32 is a fixed-dose combination of ... U.S. Patent No. 8,815,889 claims methods for treating insulin ... patent expires in 2024. If NB32 is approved for ...
Breaking Biology Technology:Engineers develop new sensor to detect tiny individual nanoparticles 2Engineers develop new sensor to detect tiny individual nanoparticles 3Press agenda for Project LIBERTY Grand Opening 2Press agenda for Project LIBERTY Grand Opening 3Press agenda for Project LIBERTY Grand Opening 4Press agenda for Project LIBERTY Grand Opening 5Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4
... advanced tools after their brains evolved a greater capacity for ... it took early humans almost two million years to move ... used computer modelling and tiny sensors embedded in gloves to ... order to make two types of tools during the Lower ...
... 2010Scientists at the U.S. Department of Energy,s Los Alamos ... thin films capable of absorbing light and generating electric ... in the journal Chemistry of Materials, could ... "Potentially, with future refinement of this technology, windows in ...
... Colo., Nov. 3, 2010 Bolder BioTechnology, Inc. today ... $1.2 million in Qualifying Therapeutic Discovery Project Grants.  Grants ... Discovery Project Tax Credit Program, which authorized up to ... companies with 250 or fewer employees.   ...
Cached Biology Technology:Stone Age humans needed more brain power to make big leap in tool design 2Scientists produce transparent, light-harvesting material 2Bolder BioTechnology Announces $1.2 Million in Qualifying Therapeutic Discovery Project Grants 2
(Date:9/2/2014)... limestone is well known as a result of ... (for example, Archaeopteryx). Now, for the first time, ... equivalent of these outcrops - discoveries which include ... treader. , Despite the abundance of fossils in ... obtained from the Late Kimmeridgian equivalents of these ...
(Date:9/2/2014)... people take stress in stride; others are done in ... the molecular mechanisms of this so-called stress gap in ... that could lead researchers to better understand the development ... "Like people, each animal has unique experiences as it ... life experiences can alter the expression of genes, and ...
(Date:9/1/2014)... ─ Dietary quality in the U.S. has improved steadily ... fat intakebut overall dietary quality remains poor and disparities ... to a new study from Harvard School of Public ... evidence to date that the extensive efforts by many ... having some payoff, but it also indicates that these ...
Breaking Biology News(10 mins):Exceptionally well preserved insect fossils from the Rhône Valley 2Discovery hints at why stress is more devastating for some 2Discovery hints at why stress is more devastating for some 3Quality of US diet shows modest improvement, but overall remains poor 2Quality of US diet shows modest improvement, but overall remains poor 3
... British Columbia researchers are part of an international team ... a step they hope will lead to a universal ... conservation efforts. Barcodes based on portions of DNA ... have already emerged as a viable solution for ...
... The most comprehensive analysis yet of the genome of childhood ... the genetic blueprint, suggesting the cancer arises from just a ... Children,s Research Hospital. The research appears in the July 27 ... of Sciences . "Our data raise the ...
... BOSTONThe androgen receptor a protein ignition switch ... a master of adaptability. When drug therapy deprives the ... receptor manages to find an alternate growth route. A ... University scientists demonstrates how. The shift from androgen-dependent to ...
Cached Biology News:UBC researchers help push for standard DNA barcodes for plants 2Comprehensive look at rare leukemia finds relatively few genetic changes launch disease 2Comprehensive look at rare leukemia finds relatively few genetic changes launch disease 3Study reveals a reprogrammed role for the androgen receptor 2
Our original highly-purified, robust Taq Polymerase which delivers consistently high yields and minimal background...
A formulation of our Biolase DNA Polymerase which contains a Red Loading Dye...
... Neogens enzyme-linked immunosorbent assay (ELISA) ... as screening devices for the detection of ... The kits are intended for forensic use ... samples be confirmed by a quantitative method ...
... SUPERaseIn RNase Inhibitor (patent pending) is ... that noncovalently binds and inhibits the most ... B, C, 1 and T1. SUPERaseIn can ... contamination could be problematic. It is ideal ...
Biology Products: